Comparative Pharmacology
Head-to-head clinical analysis: ACETAZOLAMIDE versus DARANIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACETAZOLAMIDE versus DARANIDE.
ACETAZOLAMIDE vs DARANIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reversible inhibition of carbonic anhydrase, primarily in the proximal renal tubule, reducing hydrogen ion secretion and increasing bicarbonate, sodium, potassium, and water excretion. Also reduces aqueous humor formation via ocular carbonic anhydrase inhibition.
Carbonic anhydrase inhibitor. Inhibits carbonic anhydrase in the proximal renal tubule, reducing bicarbonate reabsorption and causing alkaline diuresis.
250-500 mg orally twice daily or 250 mg intravenously twice daily; for edema, 250-375 mg orally once daily; for altitude sickness, 250 mg orally every 8-12 hours.
50 mg orally once or twice daily; maximum 100 mg/day.
None Documented
None Documented
Clinical Note
moderateAcetazolamide + Atorvastatin
"The risk or severity of adverse effects can be increased when Acetazolamide is combined with Atorvastatin."
Clinical Note
moderateAcetazolamide + Diclofenamide
"The risk or severity of adverse effects can be increased when Acetazolamide is combined with Diclofenamide."
Clinical Note
moderateAcetazolamide + Fosphenytoin
"The risk or severity of adverse effects can be increased when Acetazolamide is combined with Fosphenytoin."
Clinical Note
moderateTerminal half-life approximately 10–15 hours; prolonged in renal impairment (up to 30+ hours).
Terminal elimination half-life: 2.5-3.5 hours (prolonged in renal impairment). Clinical context: Short half-life necessitates multiple daily dosing for sustained diuretic effect.
Renal: ~90% unchanged drug via tubular secretion and glomerular filtration; minor biliary/fecal (<2%).
Renal: unchanged drug (approximately 50% of absorbed dose) and metabolites. Biliary/fecal: minimal.
Category C
Category C
Carbonic Anhydrase Inhibitor
Carbonic Anhydrase Inhibitor
Acetazolamide + Phenytoin
"The risk or severity of adverse effects can be increased when Acetazolamide is combined with Phenytoin."